The Southwest Oncology Group is an adult, multi-disease, multi-modality clinical cancer research organization with 35 Member Institutions, 29 Community Clinical Oncology Program (CCOP) institutions, including 7 Minority-Based CCOPs, 27 Urologic Cancer Outreach Program (UCOP) members, and a network of 1,036 Affiliate Program investigators at 189 offices and hospitals, and 12 institutions participating in the CTEP Minority program. A special emphasis of the Group is managed by the renamed Committee on Special Populations, established in 1992. The committee's research and education agenda has broadened to include: women (or men), older cancer patients, cancer survivors, and raciallethnic minority groups (African-American, Hispanic Americans and Asian American Pacific Islanders). Involving patient advocates in Group activities is an important role of this committee. The committee report details the cross-committee research and publications. The moral and ethical conduct of clinical research by the group members is emphasized by ethics training, the conflict of interest policy, affirmation of integrity and data and safety monitoring. In addition to the presentation of correlative science activities tied to tumor banks related to disease committees, we propose a Correlative Sciences Committee, which will provide oversight of science and quality assurance of assay technology across the six Disease Committee correlative science programs in the Group. There are three new initiatives in this application. Two new adult medical oncology intergroup proposals, one dealing with advanced gynecologic cancer, the U.S. Gynecology Intergroup, and the second dealing with sarcomas, The U.S.ICanada Sarcoma Intergroup. The third is the Early Therapeutics Committee, which will take advantage of the 10 institutions in the Group who hold Phase I NCI funded U-01s. This will be possible with the new Web-Based, Multi-User Phase I Monitoring System implemented by our Statistical Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
7U10CA032102-35
Application #
8754648
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1981-07-16
Project End
2014-12-31
Budget Start
2013-12-11
Budget End
2014-12-31
Support Year
35
Fiscal Year
2013
Total Cost
$7,961,105
Indirect Cost
$1,309,127
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Glitza, Isabella C; Lu, Gary; Shah, Rupin et al. (2015) Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma 56:602-7
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-40
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Martinez, Erin E; Darke, Amy K; Tangen, Catherine M et al. (2014) A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res (Phila) 7:950-7
Mavroidis, Panayiotis; Giantsoudis, Drosoula; Awan, Musaddiq J et al. (2014) Consequences of anorectal cancer atlas implementation in the cooperative group setting: radiobiologic analysis of a prospective randomized in silico target delineation study. Radiother Oncol 112:418-24
Hills, Robert K; Castaigne, Sylvie; Appelbaum, Frederick R et al. (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15:986-96
Advani, Anjali S; McDonough, Shannon; Coutre, Steven et al. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 165:504-9
Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9
Coughlin, Kathleen; Anchoori, Ravi; Iizuka, Yoshie et al. (2014) Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res 20:3174-86
Coutre, Steven E; Othus, Megan; Powell, Bayard et al. (2014) Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol 165:497-503

Showing the most recent 10 out of 542 publications